Patents Examined by Marianne DiBrino
-
Patent number: 11957729Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 12, 2019Date of Patent: April 16, 2024Assignee: Immatics Biotechnologies GmbHInventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
-
Patent number: 11952431Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.Type: GrantFiled: December 27, 2022Date of Patent: April 9, 2024Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEIDCAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Zvika Granot, Zvi Gregorio Fridlender, Sandra Vols
-
Patent number: 11939595Abstract: This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including T-helper lymphocytes, for use as a powerful tool for immunotherapy.Type: GrantFiled: August 23, 2019Date of Patent: March 26, 2024Assignee: The Johns Hopkins UniversityInventors: Jonathan Schneck, Mathias Oelke, Karlo Perica
-
Patent number: 11939354Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: September 25, 2023Date of Patent: March 26, 2024Assignee: KING FAISAL UNIVERSITYInventor: Mahmoud Kandeel
-
Patent number: 11904053Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.Type: GrantFiled: October 27, 2020Date of Patent: February 20, 2024Assignee: MEDIMMUNE LIMITEDInventors: Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'Sa, Saba Ghazvini
-
Patent number: 11866461Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: May 16, 2023Date of Patent: January 9, 2024Assignee: KING FAISAL UNIVERSITYInventor: Mahmoud Kandeel
-
Patent number: 11859176Abstract: A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.Type: GrantFiled: December 21, 2018Date of Patent: January 2, 2024Assignees: Industrial Technology Research Institute, National Taiwan University HospitalInventors: Cheng-Tai Chen, Chien-An Chen, Wen-Ting Chiang, Su-Feng Chiu, Pei-Shin Jiang, Jih-Luh Tang, Chien-Ting Lin, Xuan-Hui Lin
-
Patent number: 11833220Abstract: Provided are an artificial multi-antigen fusion protein and a preparation method thereof. The fusion protein can effectively stimulate CD8+T and CD4+ T cell immunities, and can be applied to immunodiagnostics or serve as a prophylactic or therapeutic vaccine.Type: GrantFiled: December 15, 2015Date of Patent: December 5, 2023Assignees: Oxford Vacmedix UK Ltd.Inventors: Shisong Jiang, Xiaobing Xia, Hanghai Ding
-
Patent number: 11819516Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.Type: GrantFiled: November 4, 2016Date of Patent: November 21, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Fei Wen, Mason Smith
-
Patent number: 11813318Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.Type: GrantFiled: July 10, 2019Date of Patent: November 14, 2023Assignee: UNIVERSITY OF WASHINGTONInventors: David W. Russell, Roli K. Hirata
-
Patent number: 11807675Abstract: The present invention relates to, in part, artificial antigen presenting cells that are useful in treating disease (including cancers) and have uses, for example, directly in vivo and/or in the expansion of a patients cells for re-introduction ex vivo.Type: GrantFiled: October 3, 2014Date of Patent: November 7, 2023Assignee: The University of Maryland, BaltimoreInventors: Tonya Webb, Carolyn Morris, James East
-
Patent number: 11789019Abstract: The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).Type: GrantFiled: August 1, 2019Date of Patent: October 17, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Bruce Steven Klein, Marcel Wuethrich
-
Patent number: 11787849Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.Type: GrantFiled: September 23, 2016Date of Patent: October 17, 2023Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Patent number: 11766456Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4(+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.Type: GrantFiled: April 1, 2021Date of Patent: September 26, 2023Inventors: Bo Kyung Min, Hana Choi, Yu Kyeong Hwang
-
Patent number: 11732020Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: GrantFiled: June 16, 2017Date of Patent: August 22, 2023Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian Ellinger, Carina Wehner, Manon Weis, Susanne Wilde, Dolores Schendel
-
Patent number: 11717488Abstract: The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.Type: GrantFiled: June 18, 2021Date of Patent: August 8, 2023Assignee: Elektrofi, Inc.Inventors: Paul Brown, Lyndon Fitzgerald Charles, Jr., Chase Spenser Coffman, Daniel Benjamin Dadon, James Ivey, Lisa Liu, Chaitanya Sudrik
-
Patent number: 11698375Abstract: A method for producing an examination reagent includes adding a helper ligand to a receptor protein which is unfolded in an initial solution so as to provide a pre-solution of the examination reagent with a receptor protein which is folded. The receptor protein which is folded comprises a bonded helper ligand which can be exchanged with an examination peptide.Type: GrantFiled: July 1, 2019Date of Patent: July 11, 2023Assignee: CONSTRUCTOR UNIVERSITY BREMEN GGMBHInventors: Sebastian Hartmut Springer, Sunil Kumar Saini
-
Patent number: 11649288Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.Type: GrantFiled: February 6, 2018Date of Patent: May 16, 2023Assignee: Seattle Children's HospitalInventors: Michael C. Jensen, James Matthaei
-
Patent number: 11633429Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.Type: GrantFiled: February 10, 2022Date of Patent: April 25, 2023Assignee: Baylor College of MedicineInventors: Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso
-
Patent number: 11633428Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.Type: GrantFiled: February 10, 2022Date of Patent: April 25, 2023Assignee: Baylor College of MedicineInventors: Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso